Accession Number:

ADA458484

Title:

Development of Biologically Based Therapies for Basal-Like Tumors

Descriptive Note:

Annual summary 21 Mar 2005-20 Mar 2006

Corporate Author:

NORTH CAROLINA UNIV AT CHAPEL HILL

Personal Author(s):

Report Date:

2006-04-01

Pagination or Media Count:

15.0

Abstract:

The basal-like subtype of breast cancer is both estrogen receptor and HER2 negative and therefore is not effectively treated by hormonal therapy or trastuzamab. The purpose of this research is to identify treatment options for this subset of breast cancer patients. Breast cell lines of basal-like and luminal origin were treated with five different chemotherapeutics to determine sensitivity levels. The basal-like cell lines were more sensitive to carboplatin than luminal lines. Next, we focused on identifying a biologic therapy targeting the basal-like subtype. HER1EGFR is expressed in approximately 50 of the basal-like tumors while not expressed in the luminal tumors. The basal-like cell lines showed an increased sensitivity to HER1 tyrosine kinase inhibitor, gefitinib, compared to the luminal lines. Concurrent combinations of gefitinib and four chemotherapeutics indicate that most combinations are additive to synergistic. Of particular interest is carboplatin and gefitinib, which as single agents were more sensitive in the basal-like lines are also synergistic in combination. This work is support for a clinical trial at UNC, which will treat basal-like breast cancer patients with a HER1 inhibitor with or without carboplatin.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE